Immuron (NASDAQ:IMRN) is up 17% premarket on announcing sales results for its OTC gastrointestinal and digestive health supplement Travelan, for Q1 2020 ended September 30, 2019.
Total North American sales for Travelan reached $269K AUD, up 111% YoY.
In U.S., Q1 sales grew to $232K AUD, up 81% YoY.
In Canada, Q1 sales reached $38K AUD.
Global Immuron sales expanded by +54% YoY, reaching $741K AUD.
In Australia, Travelan grew by 34%, achieving sales of $458K AUD in Q1.
https://seekingalpha.com/news/3505466-immuron-plus-17-percent-premarket-q1-2020-sales
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.